(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 August 2010 (19.08.2010)

PCT

(10) International Publication Number
WO 2010/092123 A8

(51) International Patent Classification:
A61K 31/7034 (2006.01) *A61P 3/04* (2006.01)
A61P 3/10 (2006.01) *A61P 3/06* (2006.01)

(21) International Application Number:
PCT/EP2010/051734

(22) International Filing Date:
11 February 2010 (11.02.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/152,318 13 February 2009 (13.02.2009) US

(71) Applicant *(for all designated States except US)*: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **EICKELMANN, Peter** [DE/DE]; Boehringer Ingelheim GmbH, CD Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **MARK, Michael** [DE/DE]; Boehringer Ingelheim GmbH, CD Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **SEMAN, Leo John** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877 (US). **THOMAS, Leo** [DE/DE]; Boehringer Ingelheim GmbH, CD Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **BROEDL, Uli** [DE/DE]; Boehringer Ingelheim GmbH, CD Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **GREMPLER, Rolf** [DE/DE]; Boehringer Ingelheim GmbH, CD Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(74) Agents: **HAMMANN, Heinz** et al.; c/o Boehringer Ingelheim GmbH, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
30 June 2011

(15) Information about Correction:
see Notice of 30 June 2011

(54) Title: SGLT-2 INHIBITOR FOR TREATING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETES MELLITUS, IMPAIRED GLUCOSE TOLERANCE OR HYPERGLYCEMIA

(57) Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

WO 2010/092123 A8